An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

While randomized comparative trials are needed, a relatively new treatment option for upper urinary tract cancers shows ...

There are particular reasons to investigate angiogenesis in urologic cancers, because each tumor type represents an important paradigm: clear-cell renal cancer is caused by a mutation in the ...

Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...

March 19 marks Certified Nurses Daytm, a day dedicated to recognizing nurses who have achieved the highest standards of professionalism and excellence through specialty certification. The ...

In a preclinical study, researchers at Children's Hospital of Philadelphia (CHOP) demonstrated a novel gene therapy with potentially increased effectiveness and safety for the treatment for ...

Have a story to share? The Urology Care Foundation invites you to share your experience with a urologic condition and how it has affected you or your family. Your tax-deductible gift will help support ...

David Price, a urologic oncologist, has joined the Willis Knighton Physician Network in Shreveport ... Students were tasked ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good morning, ladies and gentlemen, and thank you for standing by.

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), has achieved last patient last visit in its Phase 1b study of the investigational drug sunobinop as a potential ...

Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited understanding of the tumor immune microenvironment (TIME). The interplay between PSCC and the immune system across disease ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and upcoming drug volixibat.